Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at BMO Capital Markets

Stock analysts at BMO Capital Markets assumed coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report issued on Wednesday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $50.00 price target on the stock. BMO Capital Markets’ price target suggests a potential upside of 315.63% from the stock’s current price.

DYN has been the subject of a number of other reports. Robert W. Baird began coverage on Dyne Therapeutics in a research report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price objective for the company. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Scotiabank began coverage on Dyne Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price target on the stock. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $48.85.

Dyne Therapeutics Trading Up 4.6 %

Shares of DYN stock opened at $12.03 on Wednesday. The stock has a 50 day moving average of $15.33 and a 200 day moving average of $25.82. The stock has a market cap of $1.36 billion, a P/E ratio of -3.38 and a beta of 1.11. Dyne Therapeutics has a twelve month low of $11.18 and a twelve month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, research analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DYN. State of New Jersey Common Pension Fund D purchased a new position in shares of Dyne Therapeutics during the 3rd quarter worth approximately $1,588,000. Jennison Associates LLC increased its stake in Dyne Therapeutics by 1.5% in the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock valued at $48,383,000 after purchasing an additional 19,730 shares in the last quarter. abrdn plc purchased a new position in Dyne Therapeutics in the 4th quarter valued at approximately $608,000. RA Capital Management L.P. increased its stake in Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after purchasing an additional 331,940 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Dyne Therapeutics by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock valued at $66,802,000 after purchasing an additional 84,760 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.